Novartis AG has been granted a speedy evaluation in the US for its latest multiple sclerosis drug ofatumumab which the company hopes can challenge the domination of Roche's same-in-class blockbuster Ocrevus.
Novartis In Line For Ofatumumab MS Approval In June
Will Rival Roche's Ocrevus
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
